Results for tag: "Bronchopulmonary Dysplasia Drug"

Bronchopulmonary Dysplasia (BPD) is a chronic lung disease that affects premature infants. It is characterized by inflammation and scarring of the lungs, leading to difficulty breathing and other respiratory problems. Treatment for BPD typically involves the use of respiratory drugs, such as bronchodilators, corticosteroids, and antibiotics. These drugs help to reduce inflammation, improve lung function, and reduce the risk of infection. In addition, oxygen therapy and mechanical ventilation may be used to help manage the symptoms of BPD. The BPD drug market is a rapidly growing segment of the respiratory drug market. It is driven by the increasing prevalence of premature births, as well as the need for improved treatments for BPD. Companies in this market include GlaxoSmithKline, AstraZeneca, Merck, and Novartis, among others. These companies are focused on developing new drugs and therapies to improve the treatment of BPD. Show Less Read more